Shadi Karimifard

North Bethesda, MD — August 14, 2026 — Expion Health®, a leader in next-generation prescription economics, announced it has been ranked on the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. This marks Expion’s second consecutive appearance on the Inc. 5000 and a significant rise from its ranking. In one year, … Expion Health’s Accelerating Growth Earns Second Consecutive Inc. 5000 Recognition

This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationJIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who … Rx Insights from July ’26

The headline sounds scary. The reality is more nuanced. When “100% pharmaceutical tariff” started circulating in headlines, it was easy to imagine a world where common medications double in price overnight. That’s not what’s happening, at least not yet, and possibly not at all for most drugs. What happened: in April 2026, the federal government … Pharmaceutical Tariffs Are Here. Will Drug Prices Actually Go Up?

This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationUTEBZI (tebipenem pivoxil) is FDA approved to treat complicated urinary tract infections (cUTI), including pyelonephritis, in adults with limited or no … Rx Insights from June ’26

Waiting for Your PBM to Tell You What Changed Isn’t a Strategy Most plan sponsors receive annual formulary updates from their PBM, review the member disruption report, and move forward. What they often don’t receive is the financial analysis behind those changes: the net cost impact, the alternatives that were considered, or whether those decisions … Your PBM Tells You What Changed. Who’s Telling You Why?

This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationLANGLARA (insulin glargine-aldy) is an FDA-approved biosimilar to Lantus and is indicated to improve glycemic control in adults and pediatric patients … Rx Insights from May ’26